Add To Watchlist
Share URL
About The Company
Description
Nanexa AB (publ) operates as a nanotechnology drug delivery company.
Read More
Overview
Value
3
Growth
21
Health
53
Management
59
Analyst Opinion
63
Total
40
All Scores Out Of 100
Best Features
- Earnings growth has improved recently
- Has a low level of debt
- Low risk of bankruptcy
- Low preportion of income is paid as dividend
Risk Factors
- Overvalued on cashflow basis
- Income is not covering expenditure and investment
- Earnings are negative
- There is a history of diluting shareholders
- No margin of safety at their current market price
- Poor earnings and cashflow growth
- Accounting anomalies: Growing revenues without a corresponding growth in cash flows. 0
Market Peers
NANEXA.ST
Key Figures
PE Ratio (TTM)
N/A
Margin Of Safety (DCF)
-82.30%
Revenue Growth (5 Year Average)
19.68%
Ratings Consensus
Neutral
Share Buybacks
-50.28%
Dividend Yeild (TTM)
N/A
Valuation
Value Score
3
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: < 0.8 SEK ✘
Current Price: 3.9 SEK
Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
N/Ax
Free Cashflow Yeild
-29.65%
PE/Earnings Growth
N/A
Price/Book
2.14x
Growth
Growth Score
21
- ✔ 5 Year Average Revenue growth of 19.68% is higher than the market average (10.97%)
- ✔ Revenue growth has improved this yeara
- ✔ Earnings growth has improved this year
- ✘ 5 Year Average Earnings growth of 0.48% is lower than the market average (14.48%)
- ✘ 5 Year Average Free Cashflow growth of -19.06% is lower than the market average (12.35%)
- ✘ Free Cashflow growth has slowed this year
Revenue Growth
19.68%
Earnings Growth
0.48%
Cashflow Growth
-19.06%
Health
Health Score
53
Altman Z Score
4.17
Piostroski Score
2.00
Debt/Equity
0.03x
Current Assets/Liabilities
9.84x
Free Cashflow/Total Debt
N/Ax
Debt/Capital
0.04x
Management
Management Score
59
Average Buybacks/Dilution
-50.28%
Recent Buybacks/Dilution
70.33%
5 Year Price Volitility
29.99%
Return On Assets
-37.15%
Return On Capital Employed
-11.86%
Return On Equity
-40.52%
Return On Free Cashflow
162.92%
Return On Investments
-6130255.60%
Analysts
Analyst Opinion
63
- ✔ Ratings consensus is Neutral
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Nanexa AB (publ)
Currency
SEK
Beta
0.555294
Vol Avg
207502
Ceo
Mr. David Westberg
Cik
Cusip
Exchange
Stockholm Stock Exchange
Full Time Employees
19
Industry
Drug Manufacturers—Specialty & Generic
Sector
Healthcare
Ipo Date
2015-06-17
Address
Virdings AllE 32B
City
Uppsala
State
Country
SE
Zip
75450
Phone
46 18 10 03 00
All financial data provided by FMP